Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis

被引:20
|
作者
Srivastava, Shivani [2 ]
Macaubas, Claudia
Deshpande, Chetan
Alexander, Heather C. [3 ]
Chang, Sheng-Yung [3 ]
Sun, Yue
Park, Jane L. [4 ]
Lee, Tzielan [4 ]
Begovich, Ann [3 ]
Mellins, Elizabeth D. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Pediat, Program Immunol, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Biol, Stanford, CA 94305 USA
[3] Celera, Alameda, CA USA
[4] Stanford Univ, Dept Pediat, Div Pediat Rheumatol, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
Systemic juvenile arthritis; Monocytes; Apoptosis; MIGRATION INHIBITORY FACTOR; MACROPHAGE ACTIVATION SYNDROME; TUMOR-NECROSIS-FACTOR; CELL-DEATH APOPTOSIS; RHEUMATOID-ARTHRITIS; PERIPHERAL-BLOOD; FAS LIGAND; GENE-EXPRESSION; ALVEOLAR MACROPHAGES; CASPASE-8; ACTIVATION;
D O I
10.1016/j.clim.2010.04.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated whether circulating monocytes from patients with systemic juvenile idiopathic arthritis (SJIA) are resistant to apoptosis and which apoptotic pathway(s) may mediate this resistance. A microarray analysis of peripheral blood mononuclear cells (PBMC) of SJIA samples and RT-PCR analysis of isolated monocytes showed that monocytes from active SJIA patients express transcripts that imply resistance to apoptosis. SJIA monocytes incubated in low serum show reduced annexin binding and diminished FasL up-regulation compared to controls. SJIA monocytes are less susceptible to anti-Fas-induced apoptosis and, upon activation of the mitochondrial pathway with staurosporine, show diminished Bid cleavage and Bcl-w down-regulation compared to controls. Exposure to SJIA plasma reduces responses to apoptotic triggers in normal monocytes. Thus, SJIA monocytes are resistant to apoptosis due to alterations in both the extrinsic and intrinsic apoptosis pathways, and circulating factors associated with active SJIA may confer this phenotype. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:257 / 268
页数:12
相关论文
共 50 条
  • [31] Malar Rash in Systemic Juvenile Idiopathic Arthritis
    Muskardin, Theresa Wampler
    Binstadt, Bryce A.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (10) : 2187 - 2187
  • [32] Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis
    Nigrovic, Peter A.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (52) : 15785 - 15786
  • [33] MEFV mutations in Systemic Juvenile Idiopathic Arthritis
    Aktay, Ayaz N.
    Bilginer, Y.
    Yilmaz, E.
    Erguven, M.
    Besbas, N.
    Topaloglu, R.
    Bakkaloglu, A.
    Ozen, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (02) : 217 - 217
  • [34] Thalidomide for systemic onset juvenile idiopathic arthritis
    K. Sathe
    Raju P. Khubchandani
    Indian Pediatrics, 2013, 50 : 237 - 239
  • [35] Biologic therapies in systemic juvenile idiopathic arthritis
    Batu, Ezgi Deniz
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (06): : 621 - 629
  • [36] Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management
    Sathish Kumar
    The Indian Journal of Pediatrics, 2016, 83 : 322 - 327
  • [37] Canakinumab for the treatment of systemic juvenile idiopathic arthritis
    Grom, Alexei A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (11) : 1427 - 1435
  • [38] JAK inhibitors in systemic juvenile idiopathic arthritis
    He, Tingyan
    Xia, Yu
    Luo, Ying
    Yang, Jun
    FRONTIERS IN PEDIATRICS, 2023, 11
  • [39] Tapering canakinumab in systemic juvenile idiopathic arthritis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2020, 2 (10): : E593 - E593
  • [40] Extracellular vesicles in systemic juvenile idiopathic arthritis
    Maller, Justine
    Morgan, Terry
    Morita, Mayu
    McCarthy, Frank
    Jung, Yunshin
    Svensson, Katrin J.
    Elias, Joshua E.
    Macaubas, Claudia
    Mellins, Elizabeth
    JOURNAL OF LEUKOCYTE BIOLOGY, 2023, 114 (05) : 387 - 403